Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-18

Clinical Trial Update: Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2) [Phase 3]

View source ↗

Summary

Phase 3 trial update for fluvoxamine in early treatment of Covid-19 (Stop Covid 2) has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fluvoxamine (fluvoxamine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Covid19, Coronavirus | Phase 3 | Status: COMPLETED | Results posted: 2022-10-18